Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.

Clinical Lung Cancer（2018）

引用 53|浏览61

暂无评分

摘要

Subgroup analyses of the LL3, LL6, and LL7 trials show that afatinib is an effective and tolerable treatment for patients with EGFRm NSCLC, independent of age.

查看译文

关键词

EGFR blocker,Elderly,Gefitinib,NSCLC,Tyrosine kinase inhibitor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要